Table 1a.
Sorafenib arm (n = 382) | Placebo arm (n = 388) | |
---|---|---|
Mean ± SD number of target lesions used | 2.1 ± 0.9 | 2.1 ± 0.9 |
Mean ± SD baseline tumor size (mm) | 78.0 ± 55.1 | 79.6 ± 52.1 |
RR by RECIST at 6 weeks | 10.5 % | 1.0% |
Mean ± SD % change in tumor size at 6 weeks vs. baseline | −5.9% ± 28.6% | 15.3% ± 32.6% |
Mean log ratio ± SD of tumor size at 6 weeks vs. baseline | −0.10 ± 0.29 | 0.11 ± 0.25 |